Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancercell lungsmall cellnon smallnsclc
  Phrases that lowered it: combinationsubjectsthis trialwithin weeksconducted
• Sponsor's past termination rate: 17.2% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports marked serious: 44.9% (lowers risk) · Drug's FDA history
• Phase: 1 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 8.4% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 75 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 262 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 2 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 6881 (lowers risk) · Drug's FDA history
• Disease area, respiratory: Yes (raises risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Keywords listed: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers NCT06130254 · started 2024 · scored riskier than 70% of active trials terminated
• PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors NCT02022982 · started 2014 · scored riskier than 79% of active trials completed
• Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 · started 2021 · scored riskier than 89% of active trials terminated
• Palbociclib and Binimetinib in Advanced Triple Negative Breast Cancer NCT04494958 · started 2020 · scored riskier than 83% of active trials completed
• A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung NCT02185690 · started 2017 · scored riskier than 95% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.